Elke Pertler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elke Pertler has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Benedikt Schaefer
Department of Medicine I, Medical University of Innsbruck, Innsbruck, Austria
4 shared publications - Heinz Zoller
Department of Medicine I, Gastroenterology, Hepatology and Endocrinology, Medical University of Innsbruck, Innsbruck, Austria
4 shared publications - Herbert Tilg
Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medizinische Universitat Innsbruck, Innsbruck, Austria
4 shared publications - Marlene Panzer
Medical University of Innsbruck, Innsbruck, Austria
3 shared publications - Sonja Astrid Wagner
Christian Doppler Laboratory for Iron and Phosphate Biology, Department of Internal Medicine I Medical University of Innsbruck Innsbruck Austria
3 shared publications Bettina Sarg
Institute of Medical Biochemistry, Protein Core Facility, Biocenter Medical University of Innsbruck Innsbruck Austria
2 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 17 (6)
Remodelling of Skeletal Muscle During Iron Deficiency Anaemia and Recovery After Intravenous Iron Therapy
Background: The global prevalence of iron deficiency anaemia (IDA) is about 25% and even higher in women of reproductive age and children. IDA can impair skeletal muscle by disrupting oxygen utilization, energy production and contractile function. Haematological effects of intravenous (IV) iron therapy in IDA are well studied, but its impact on muscle and energy metabolism is less clear. We investigated the molecular and functional effects of IDA on skeletal muscle in a mouse model and C2C12 myotubes. The effects of different IV iron formulations on skeletal muscle were compared in iron deficient C2C12 myotubes, in IDA‐mice and patients with IDA. Methods: Treatment effects of the IV iron formulations ferric carboxymaltose (FCM) and ferric derisomaltose (FDI) were studied in IDA mice by tail vein injection of 2‐mg iron. Analyses were carried out 7 days and 4 weeks post‐treatment. C2C12 myotubes were treated with desferrioxamine, followed by incubation with FCM or FDI before mitochondrial respiration, gene expression and metabolite profiles were analysed. Respiratory muscle function was investigated in adults with IDA treated with FCM or FDI as exploratory endpoint in a randomized clinical trial. Results: In our mouse model IDA induced a trend towards impaired skeletal muscle function and a shift to anaerobic metabolism. Only treatment with FDI resulted in a significant increase in muscle type I and type IIb fibre cross‐sectional area when compared to IDA. FDI also induced earlier recovery of contractile protein expression and energy metabolism than FCM. Exploratory proteomic and metabolic analyses revealed that treatment with FDI might restore mitochondrial enzymes and reduce lactate accumulation after 7 days. In vitro, iron‐deficient C2C12 myotubes showed reduced mitochondrial respiration and increased glycolysis with partial recovery by both IV iron formulations. Two weeks after treatment of IDA in adults, FDI caused a significantly better improvement in maximal expiratory pressure than FCM (mean pressure difference between treatments 5.06 cmH 2 O, p = 0.013). This difference appeared unrelated to post‐treatment hypophosphatemia. Conclusions: IDA shows a trend towards impaired skeletal muscle function through metabolic and structural remodelling in mice, which is restored with different kinetics by FDI and FCM. These findings are in accord with exploratory findings from a clinical study indicating better respiratory muscle recovery in FDI‐treated than FCM‐treated IDA patients. Cell culture experiments confirm the effects of IDA on impaired metabolism but did not show differential effects of FCM and FDI. Different tissue pharmacokinetics could explain the distinct in vivo response of both formulations.
- 4 November 2026
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 17 (6)
Open AccessRemodelling of Skeletal Muscle During Iron Deficiency Anaemia and Recovery After Intravenous Iron Therapy
Background: The global prevalence of iron deficiency anaemia (IDA) is about 25% and even higher in women of reproductive age and children. IDA can impair skeletal muscle by disrupting oxygen utilization, energy production and contractile function. Haematological effects of intravenous (IV) iron therapy in IDA are well studied, but its impact on muscle and energy metabolism is less clear. We investigated the molecular and functional effects of IDA on skeletal muscle in a mouse model and C2C12 myotubes. The effects of different IV iron formulations on skeletal muscle were compared in iron deficient C2C12 myotubes, in IDA‐mice and patients with IDA. Methods: Treatment effects of the IV iron formulations ferric carboxymaltose (FCM) and ferric derisomaltose (FDI) were studied in IDA mice by tail vein injection of 2‐mg iron. Analyses were carried out 7 days and 4 weeks post‐treatment. C2C12 myotubes were treated with desferrioxamine, followed by incubation with FCM or FDI before mitochondrial respiration, gene expression and metabolite profiles were analysed. Respiratory muscle function was investigated in adults with IDA treated with FCM or FDI as exploratory endpoint in a randomized clinical trial. Results: In our mouse model IDA induced a trend towards impaired skeletal muscle function and a shift to anaerobic metabolism. Only treatment with FDI resulted in a significant increase in muscle type I and type IIb fibre cross‐sectional area when compared to IDA. FDI also induced earlier recovery of contractile protein expression and energy metabolism than FCM. Exploratory proteomic and metabolic analyses revealed that treatment with FDI might restore mitochondrial enzymes and reduce lactate accumulation after 7 days. In vitro, iron‐deficient C2C12 myotubes showed reduced mitochondrial respiration and increased glycolysis with partial recovery by both IV iron formulations. Two weeks after treatment of IDA in adults, FDI caused a significantly better improvement in maximal expiratory pressure than FCM (mean pressure difference between treatments 5.06 cmH 2 O, p = 0.013). This difference appeared unrelated to post‐treatment hypophosphatemia. Conclusions: IDA shows a trend towards impaired skeletal muscle function through metabolic and structural remodelling in mice, which is restored with different kinetics by FDI and FCM. These findings are in accord with exploratory findings from a clinical study indicating better respiratory muscle recovery in FDI‐treated than FCM‐treated IDA patients. Cell culture experiments confirm the effects of IDA on impaired metabolism but did not show differential effects of FCM and FDI. Different tissue pharmacokinetics could explain the distinct in vivo response of both formulations.
- Top Cited PapersOpen Access
- 18 March 2026
- Published by American Society of Hematology in Blood
Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia
Modern intravenous (IV) iron formulations allow treatment of iron deficiency anemia (IDA) with one or two infusions. Ferric carboxymaltose (FCM) is a widely used IV iron, which causes hypophosphatemia in the majority of patients. Osteomalacia and fractures are increasingly recognized after repeated infusions of FCM. It is unknown why ferric derisomaltose (FDI) rarely causes hypophosphatemia. In this study, we compare the effects of FCM and FDI on fracture risk and investigate potential underlying mechanisms explaining different effects on bone- and mineral-metabolism. For this aim, fracture rate and osteomalacia were assessed in a cohort of 357 patients treated with either drug, which reported a significantly higher rate of incident osteomalacia or fracture after FCM. These findings were validated in over 20,000 patients from the TriNetX database, where FCM-treatment was independently associated with a higher fracture risk compared with FDI. The underlying mechanisms were investigated in a mouse model of IDA treated with FCM or FDI, an osteocyte model and biochemically. FCM caused lower expression of collagen and ossification genes, associated with significantly higher bone iron concentrations than FDI. Electron microscopy showed iron-loaded vesicles in osteoblasts and early osteocytes. FCM but not FDI inhibited binding of dentin matrix protein 1 to [alpha]V[beta]3-integrin on osteocytes. This is a potential mechanism for reduced bone formation and higher levels of intact fibroblast-growth factor-23 after FCM. Our data report that IDA and FCM treatment can directly impair bone formation and increase fracture risk.
- 18 March 2026
- Published by American Society of Hematology in Blood
Top Cited PapersOpen AccessFerric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia
Modern intravenous (IV) iron formulations allow treatment of iron deficiency anemia (IDA) with one or two infusions. Ferric carboxymaltose (FCM) is a widely used IV iron, which causes hypophosphatemia in the majority of patients. Osteomalacia and fractures are increasingly recognized after repeated infusions of FCM. It is unknown why ferric derisomaltose (FDI) rarely causes hypophosphatemia. In this study, we compare the effects of FCM and FDI on fracture risk and investigate potential underlying mechanisms explaining different effects on bone- and mineral-metabolism. For this aim, fracture rate and osteomalacia were assessed in a cohort of 357 patients treated with either drug, which reported a significantly higher rate of incident osteomalacia or fracture after FCM. These findings were validated in over 20,000 patients from the TriNetX database, where FCM-treatment was independently associated with a higher fracture risk compared with FDI. The underlying mechanisms were investigated in a mouse model of IDA treated with FCM or FDI, an osteocyte model and biochemically. FCM caused lower expression of collagen and ossification genes, associated with significantly higher bone iron concentrations than FDI. Electron microscopy showed iron-loaded vesicles in osteoblasts and early osteocytes. FCM but not FDI inhibited binding of dentin matrix protein 1 to [alpha]V[beta]3-integrin on osteocytes. This is a potential mechanism for reduced bone formation and higher levels of intact fibroblast-growth factor-23 after FCM. Our data report that IDA and FCM treatment can directly impair bone formation and increase fracture risk.
- 29 October 2025
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 138 (11-12) , 357-369
Preoperative anemia, transfusions and survival in colorectal cancer surgery—A retrospective study
Summary Perioperative anemia and blood transfusions are frequent and both are associated with a worse outcome in patients undergoing colorectal cancer surgery. To assess if treatment of anemia by transfusions can improve outcome, we conducted the present retrospective analysis. Of all patients who underwent elective colorectal cancer surgery at the University Hospital of Innsbruck between 2010 and 2019, 654 patients could be included in the study. The impact of preoperative anemia and transfusion on 1‑year survival was assessed using Kaplan-Meier analysis, univariate and multivariate Cox regression and inverse probability treatment weighting models to estimate the effects of preoperative transfusion on outcome. Preoperative anemia was present in 62.4% of patients and was the strongest predictor of perioperative transfusions. Intraoperative or postoperative transfusion occurred in 30.3% of the cohort, with higher rates in anemic patients. The transfusion rate was 36% between 2010 and 2015 and 25% in patients who underwent surgery from 2015 onwards. The 1‑year survival was significantly lower in transfused compared to nontransfused patients. After adjusting for age, sex and hemoglobin, transfusions and anemia were no longer independent predictors of survival. Elevated C‑reactive protein (CRP), higher tumor stage, age and minimally invasive surgery were identified as the main independent predictors of 1‑year mortality. Preoperative anemia predicts a higher rate of perioperative transfusions and is associated with worse 1‑year survival after colorectal cancer surgery. Transfusions do not correct impaired survival in patients with anemia. These findings underline the importance of proactive anemia management before surgery to improve postoperative outcome.
- 29 October 2025
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 138 (11-12) , 357-369
Preoperative anemia, transfusions and survival in colorectal cancer surgery—A retrospective study
Summary Perioperative anemia and blood transfusions are frequent and both are associated with a worse outcome in patients undergoing colorectal cancer surgery. To assess if treatment of anemia by transfusions can improve outcome, we conducted the present retrospective analysis. Of all patients who underwent elective colorectal cancer surgery at the University Hospital of Innsbruck between 2010 and 2019, 654 patients could be included in the study. The impact of preoperative anemia and transfusion on 1‑year survival was assessed using Kaplan-Meier analysis, univariate and multivariate Cox regression and inverse probability treatment weighting models to estimate the effects of preoperative transfusion on outcome. Preoperative anemia was present in 62.4% of patients and was the strongest predictor of perioperative transfusions. Intraoperative or postoperative transfusion occurred in 30.3% of the cohort, with higher rates in anemic patients. The transfusion rate was 36% between 2010 and 2015 and 25% in patients who underwent surgery from 2015 onwards. The 1‑year survival was significantly lower in transfused compared to nontransfused patients. After adjusting for age, sex and hemoglobin, transfusions and anemia were no longer independent predictors of survival. Elevated C‑reactive protein (CRP), higher tumor stage, age and minimally invasive surgery were identified as the main independent predictors of 1‑year mortality. Preoperative anemia predicts a higher rate of perioperative transfusions and is associated with worse 1‑year survival after colorectal cancer surgery. Transfusions do not correct impaired survival in patients with anemia. These findings underline the importance of proactive anemia management before surgery to improve postoperative outcome.
- Open Access
- 10 March 2022
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 6 (7) , 1611-1619
Synonymous mutation in adenosine triphosphatase copper‐transporting beta causes enhanced exon skipping in Wilson disease
Wilson disease (WD) is caused by biallelic pathogenic variants in adenosine triphosphatase copper‐transporting beta (ATP7B); however, genetic testing identifies only one or no pathogenic ATP7B variant in a number of patients with WD. Synonymous single‐nucleotide sequence variants have been recognized as pathogenic in individual families. The aim of the present study was to evaluate the prevalence and disease mechanism of the synonymous variant c.2292C>T (p.Phe764=) in WD. A cohort of 280 patients with WD heterozygous for a single ATP7B variant was investigated for the presence of c.2292C>T (p.Phe764=). In this cohort of otherwise genetically unexplained WD, the allele frequency of c.2292C>T (p.Phe764=) was 2.5% (14 of 560) compared to 7.1 × 10−6 in the general population (2 of 280,964 in the Genome Aggregation Database; p < 10−5; Fisher exact test). In an independent United Kingdom (UK) cohort, 2 patients with WD homozygous for p.Phe764= were identified. RNA analysis of ATP7B transcripts from patients homozygous or heterozygous for c.2292C>T and control fibroblasts showed that this variant caused high expression of an ATP7B transcript variant lacking exon 8. Conclusion: The synonymous ATP7B variant c.2292C>T (p.Phe764=) causes abnormal messenger RNA processing of ATP7B transcripts and is associated with WD in compound heterozygotes and homozygotes.
- 10 March 2022
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 6 (7) , 1611-1619
Open AccessSynonymous mutation in adenosine triphosphatase copper‐transporting beta causes enhanced exon skipping in Wilson disease
Wilson disease (WD) is caused by biallelic pathogenic variants in adenosine triphosphatase copper‐transporting beta (ATP7B); however, genetic testing identifies only one or no pathogenic ATP7B variant in a number of patients with WD. Synonymous single‐nucleotide sequence variants have been recognized as pathogenic in individual families. The aim of the present study was to evaluate the prevalence and disease mechanism of the synonymous variant c.2292C>T (p.Phe764=) in WD. A cohort of 280 patients with WD heterozygous for a single ATP7B variant was investigated for the presence of c.2292C>T (p.Phe764=). In this cohort of otherwise genetically unexplained WD, the allele frequency of c.2292C>T (p.Phe764=) was 2.5% (14 of 560) compared to 7.1 × 10−6 in the general population (2 of 280,964 in the Genome Aggregation Database; p < 10−5; Fisher exact test). In an independent United Kingdom (UK) cohort, 2 patients with WD homozygous for p.Phe764= were identified. RNA analysis of ATP7B transcripts from patients homozygous or heterozygous for c.2292C>T and control fibroblasts showed that this variant caused high expression of an ATP7B transcript variant lacking exon 8. Conclusion: The synonymous ATP7B variant c.2292C>T (p.Phe764=) causes abnormal messenger RNA processing of ATP7B transcripts and is associated with WD in compound heterozygotes and homozygotes.